Introduction
Arterial elastic properties, central (aortic) haemodynamics and peripheral endothelial function are important predictors of cardiovascular risk. [1] [2] [3] [4] Importantly, the recent Conduit Artery Function Evaluation (CAFÉ ) study showed that a greater decrease of central blood pressure (BP) with antihypertensive treatment is associated with reduced cardiovascular events, independent of peripheral BP changes. 5 Likewise, there are data showing that the reversal of endothelial dysfunction, that is present in hypertensive patients, 6 may benefit prognosis. 7 Drugs that block the renin-angiotensin system (RAS), such as angiotensin converting enzyme (ACE) inhibitors (ACEIs), may improve cardiovascular structure and function, [8] [9] [10] [11] [12] [13] and this effect is not fully explained by the respective BP change. [8] [9] [10] 12, 14 However, different ACEIs may not confer a same degree of organoprotection, and this is perhaps due to dissimilarities in their propensity to penetrate vascular tissue and inhibit the tissue ACE. 15, 16 Although the notion of a class effect of ACEIs has been proposed, this is not fully documented or universally accepted. On the other hand, angiotensin-II type-1 receptor blockers (ARBs) efficiently block the interaction of both ACE-and non-ACEproduced angiotensin-II with type-1 receptor, and these drugs are also characterized by organoprotective effects. 17 Beyond the established benefit of long-term antihypertensive therapy, there are no data to support that acute effects of drugs -including RAS blockers -on BP and arterial function are clinically relevant in hypertensive patients. However, the acute effects of RAS blockers may be important in some other clinical settings, such as acute myocardial infarction, [18] [19] [20] coronary revascularization 19, 21 and even non-cardiac surgery. 22 Furthermore, there is evidence that different drugs of the same class (ACEIs) may not be equally beneficial in such acute conditions. 21, 23, 24 Data comparing the acute vascular effects of different RAS blockers in humans are limited. 16, [25] [26] [27] Accordingly, in the present randomized, placebo-controlled, double-blind, paralleldesign study, we investigated the acute effects of different types of RAS blockade on arterial function in a population with impaired arterial performance, using a thorough approach that evaluates endothelial function of both conductance and resistance arteries and central (aortic) haemodynamics. For this purpose, we compared the effects of captopril, quinapril (an ACEI with presumed high-tissue affinity 15, 16 ) and telmisartan (an ARB possessing a unique action profile 28 ) on subjects with essential hypertension, which may be regarded as a model of abnormal arterial function. Also, we sought to investigate whether any observed vascular changes would be associated with respective alterations of peripheral BP.
Materials and methods

Study population
We evaluated consecutive patients with mild to moderate hypertension who were referred from the Hypertension Unit to our Laboratory for vascular studies for research purposes. A full medical history was taken and physical examination was performed. Patients who had evidence of secondary hypertension, coronary artery disease, heart failure, history of a cerebrovascular event, endocrinopathy, or an acute or chronic inflammatory-infectious disease were excluded. All subjects were clinically well and taking no antioxidant vitamins, anti-inflammatory or steroid substances. No female participant was on oral contraceptives or oestrogen replacement therapy. The final study comprised 100 patients (mean age 57.2 years, 48 males).
Brachial systolic and diastolic BP (SBP and DBP) in the sitting position were measured in the right arm with a mercury sphygmomanometer on three occasions 1 min apart, after the subjects had rested for 15 min, and the mean value was calculated. Hypertension was diagnosed when BP was above 140/90 mm Hg in three different visits a week apart, or if chronic use of antihypertensive drugs was documented. In that case, medication was withdrawn for 2 weeks before the study. Subjects abstained from caffeine, ethanol and flavonoidcontaining beverages for at least 12 h before the study.
Study design
The study was carried out using a randomized, double-blind, placebo-controlled, parallel-group design. Subjects were studied in the morning after an overnight fast on two occasions, before and 2 h after drug administration, in a quiet, temperature-controlled room at 231C. After a 20-min rest period, baseline measurements for evaluation of central haemodynamics (pulse-wave analysis), of endothelial function of resistance and then of conduit arteries were taken in the supine position, in this fixed order. The study of conduit vessels was preceded by a 15-min rest period to allow recovery of vascular function. Then, the subjects were randomized to take either captopril 25 mg or quinapril 20 mg or telmisartan 80 mg, or placebo per os, together with drinking 200 ml of water. Randomization was undertaken by sealed envelopes and gave rise to four groups with 25 patients each. Dosing was supervised. In a pilot study that consisted of eight patients in each treatment arm who underwent BP measurement every 30 min after drug administration, we observed that the three active drugs caused a maximal decrease of BP approximately at 2 h. Therefore, vascular studies were repeated 2 h after drug intake in all groups.
The study protocol was approved by our Institutional Research Ethics Committee and all subjects gave informed consent.
Evaluation of central haemodynamics (pulse-wave analysis)
Central (aortic) BPs and augmentation index (AIx), an index of wave reflections, 1, 3, [29] [30] [31] were calculated using a validated, commercially available system (SphygmoCor, AtCor Medical, Sydney, Australia), which employs the principle of applanation tonometry. Waveforms of radial pressure (provided by radial artery tonometry) were calibrated according to sphygmomanometric SBP and DBP measured in the brachial artery, since there is practically negligible pressure amplification between the brachial and radial arteries. Mean arterial pressure (MAP) was then computed automatically by numerically averaging of the radial pressure waveform. 32 The central BP was derived with the use of a generalized transfer function, which is an accurate estimate of the central arterial pressure waveform. Augmented pressure (AP) is the pressure added to the incident wave by the returning reflected one and represents the pressure boost with which the left ventricle must cope at systole. AIx (defined as AP divided by pulse pressure and expressed as a percentage) is a composite measure of the magnitude of wave reflections and arterial stiffness, which affects timing of wave reflections. For similar heart rate and effective length of the arterial system, larger values of AIx indicate increased wave reflections from the periphery and/or earlier return of the reflected wave as a result of increased pulse-wave velocity (owing to increased arterial stiffness), and vice versa. 1, 3, 31 The pressure at the inflection point of the aortic waveform (P 1 ) corresponds to the peak of blood flow velocity and is a measure of the force of cardiac ejection. Arrival time (Dt) of reflected waves at aorta is the time from the foot of the pressure wave to the late systolic peak and represents the time needed for pressure waves to travel from the aorta to peripheral arterial sites and return back to the aorta owing to wave reflections. A lower Dt indicates a shorter travel time of the pressure waves and a higher arterial stiffness. 30 Absolute amplification of pulse pressure between central and peripheral arteries (in mm Hg) was calculated as brachial pulse pressureÀaortic pulse pressure, and relative amplification (in %) was calculated as ((brachial pulse pressureÀaortic pulse pressure)/ brachial pulse pressure) Â 100.
Evaluation of endothelial function in resistance vessels
The response of forearm blood flow (FBF, expressed as ml/min per 100 ml of forearm tissue volume) to reactive hyperaemia is a non-invasive method of estimating the endothelium-dependent vasodilation of the small resistance arteries.
14 FBF studies were performed in the right arm using a strain gauge venous occlusive plethysmograph (EC-5R, Hokanson DE Inc., WA, USA). Mercury-filled silastic strain gauges of appropriate size for each subject were placed about 5 cm below the antecubital crease, at the level of the maximal circumference of the forearm. A wrist cuff was inflated to 50 mm Hg above the SBP throughout the study to exclude the hand circulation. An upper arm rapid cuff inflator (E20, Hokanson DE Inc., WA, USA), which was inflated to 50 mm Hg for 7 s in each a 15 s cycle, was used to occlude intermittently venous outflow from the arm. After resting FBF was obtained, a cuff placed on the mid-forearm was inflated to suprasystolic levels (50 mm Hg above SBP), and the arterial inflow was thus interrupted. After 4.5 min, this cuff was deflated leading to reactive hyperaemia. FBF was then measured for 3 min. Resting forearm vascular resistance (FVR) was calculated as the MAP divided by resting FBF.
Evaluation of endothelial function in conductance vessels
Resting and hyperaemic diameters and flows as well as flow-mediated dilatation (FMD) of the conduit brachial artery, an estimate of endothelial function, were determined by using a linear array ultrasonic transducer (Acuson 128 XP, Mountain View, CA, USA) as described previously. 33, 34 Two-dimensional and Doppler images of the right brachial artery for diameter and flow determination were initially recorded under resting conditions. Resting mean flow velocity was assessed by a pulsed Doppler signal, from a sample volume placed in the middle part of the artery. Then, reactive hyperaemia was induced as described above. Brachial artery was continuously scanned from 30 s before to 90 s after cuff deflation. Hyperaemic mean flow velocity was measured within the first 15 s and hyperaemic diameter was measured 50-60 s after cuff release.
Ten minutes after the 2-h cuff deflation, endothelium-independent, nitrate-induced dilatation (NID) was measured after delivering a single (0.4 mg) dose of nitroglycerin spray sublingually. Images were recorded on super-VHS (Video Home System) videotape and were measured offline by the same observer, who was blinded to the image sequence and the randomization assignment. Three cardiac cycles were analysed and measurements were averaged. The mean variability for FMD measured on two different days by this observer was 1.1% (absolute value).
Brachial artery flow was calculated according to the equation: Flow (in ml/min) ¼ mean flow velocity Â heart rate Â 3.14 Â (brachial artery diameter/2) 2 . Reactive hyperaemia was expressed as the percent change of brachial artery flow from baseline: hyperaemia (in %) ¼ ((hyperaemic flowÀresting flow)/resting flow) Â 100. Shear stress (averaged over the whole cardiac cycle) was calculated using the equation: Shear stress (in dyn/cm 2 ) ¼ 8 Â m Â mean flow velocity/resting diameter, where m is the viscosity of blood. 35 FMD was calculated as the percent change of brachial artery diameter from baseline: FMD (%) ¼ ((hyperaemic diameterÀresting diameter)/resting diameter) Â 100.
Statistical analysis
Sample size calculations were based on data from our unit, which showed that the s.d. of AIx and FMD for hypertensive subjects were 8 and 2.4%, respectively. Therefore, we estimated that 22 subjects per group would provide 80% power at the 5% level of significance to detect a difference of 7% in AIx in a parallel design study. Similarly, 24 subjects per group would provide 80% power to detect an absolute difference of 2% in FMD.
Continuous variables are expressed as mean value7s.d., whereas categorical variables as absolute and/or relative frequencies. All continuous variables were tested for homogeneity of variance and normal distribution before any statistical analysis was applied, by using the Kolmogorov-Smirnov criterion. For skewed variables, data are expressed as median value (25th-75th percentile) and logarithmic transformation was performed before analysis. Within each group, comparisons of values after treatment with baseline values were carried out with paired t-test. The unpaired t-test or one-way analysis of variance (ANOVA) was used for comparisons among groups. In cases that ANOVA yielded a significant difference among treatments, isolation of the active treatment(s) that produced the difference compared to placebo was carried out by the Dunnett post hoc test. The changes of vascular parameters were adjusted for baseline values or other potential confounders with analysis of covariance (ANCOVA). Contingency tables and w 2 test or the Fisher's exact test were applied for categorical parameters. Comparisons of the time course curves of FBF during reactive hyperaemia before and after treatment within each group were carried out by two-way repeated-measures ANOVA (2 treatment points (baseline and after treatment) Â 13 time points (one FBF measurement each 15 s for 3 min)). Correlations between variables were evaluated by calculation of the Pearson correlation coefficient. Exact Po0.05 were considered statistically significant. Data analysis was performed with SPSS software, version 10.1 (SPSS Inc., Chicago, IL, USA).
Results
The effect of each active drug vs placebo is better described by reporting response, defined as mean net active drug effect minus placebo effect.
Baseline characteristics
There were no significant differences in clinical characteristics or baseline parameters of vascular function among the four study subgroups (Tables 1  and 2 Heart rate, BP and pulse-wave analysis Heart rate did not change significantly with any treatment (P ¼ NS). The changes of peripheral (brachial) BP differentiated significantly across the four treatment groups (Figure 1) (Figure 1) , whereas telmisartan had no significant effect (decrease of 4.9 mm Hg in SBP and of 3.1 mm Hg in DBP, both P ¼ NS). Interestingly, with quinapril, the reduction of central and peripheral SBP were similar (P ¼ NS); on the other hand, with captopril, the absolute decrease of aortic SBP was lower than the decrease of brachial SBP (Po0.05). ANCOVA showed that the reduction of central SBP and DBP were independent of the respective changes of peripheral BPs with quinapril (both Po0.05), but not with captopril (both P ¼ NS).
The absolute mean change of AIx was similar in men and women (À2.7 vs À3.2%, P ¼ NS) and in patients with and without previous treatment (À2.2 vs À4.1%, P ¼ NS) and correlated with the change of brachial SBP (r ¼ 0.27, Po0.01) and DBP (r ¼ 0.22, Po0.05). The four treatments differed significantly (Po0.01) with regard to the changes of AIx (Figure 2 ). Compared to placebo, AIx decreased significantly with quinapril (absolute change by 7.2%, Po0.01), decreased marginally with captopril (by 4.7%, P ¼ 0.07) and did not change with telmisartan (absolute decrease of 2.0%, P ¼ NS). After introducing baseline AIx and the change of MAP in a subsequent ANCOVA model, quinapril was still associated with a significant reduction of AIx compared to placebo (Po0.05), whereas, on the other hand, the marginal association between captopril and change of AIx disappeared (P ¼ NS).
Compared to placebo, we found a greater but nonsignificant increase of Dt with captopril (by 3.3 msec) and quinapril (by 2.8 msec) than with telmisartan (by 1.6 msec), indicating a trend for reduction of arterial stiffness with ACEIs. We also observed a greater increase of absolute and relative PP amplification with quinapril (by 2.1 mm Hg and 6.4%) than with captopril (change of À0.1 mm Hg and 2.6%) or telmisartan (change of À0.5 mm Hg and 0.6%), suggesting a higher reduction of left ventricular afterload with quinapril, but this difference was not statistically significant among groups. P 1 did not change with any treatment (P ¼ NS), indicating no effects on the force of cardiac ejection.
Brachial artery study
The change of FMD after treatment was not different between men and women (absolute mean increases of 0.80 vs 1.36%, P ¼ NS), whereas we observed a trend for a lower change in patients who were taking drugs before the study compared with never-treated patients (absolute mean increases of 0.78 vs 1.59%, P ¼ 0.1). Analysis revealed an inverse association of the increase of FMD with baseline FMD (r ¼ À0.40, Po0.001), but no correlation with age or the change of BPs (P ¼ NS).
There was a significant effect of treatment on FMD among the four groups (Po0.001, Figure 2 ). Post hoc analysis showed that this effect was attributed to an increase of FMD with quinapril (absolute increase of 2.70%, Po0.001 compared with placebo). The effects of captopril and telmisartan were not significant (absolute increases of 0.35 and 0.21%, respectively, both P ¼ NS). ANCOVA showed that the association between quinapril treatment and FMD increase was independent of baseline FMD value or previous treatment (Po0.001). This favourable effect of quinapril was due to a significant increase of brachial hyperaemic diameter (Po0.05) with quinapril (responses compared to placebo of 0.012, 0.144 and 0.028 mm after captopril, quinapril and telmisartan, respectively). No significant differences (P ¼ NS) were observed among treatments with regard to resting brachial diameter (responses of 0.004, 0.028 and 0.016 mm), resting flow, hyperaemic flow and flow velocity, degree of reactive hyperaemia or hyperaemic shear stress (responses of À1.9, À2.1 and 0.3 dyn/cm 2 ). NID values were similar among the four groups at the end of the study (9.774.3 vs 12.475.9 vs 10.475.1 vs 10.174.3% with placebo, captopril, quinapril and telmisartan, respectively, P ¼ NS).
FBF study
Compared with placebo, treatment with the three active drugs was not associated with significant changes (P ¼ NS) of resting FBF (responses of À0.1, À0.2 and 0.1 ml/min per 100 ml of tissue after captopril, quinapril and telmisartan, respectively). Likewise, resting FVR did not change significantly with treatment (responses of 1.0, À2.2 and À2.2 mm Hg/ml/min per 100 ml of tissue, P ¼ NS). Furthermore, peak hyperaemic FBF remained unaltered (P ¼ NS) after treatment (responses of 0.1, À0.5 and 0.6 ml/min per 100 ml of tissue). Finally, we did not observe any significant change of hyperaemic FBF throughout the 3-min period of hyperaemia after treatment with the three active drugs or placebo (all P ¼ NS with two-way repeated-measures ANOVA, Figure 3 ).
Discussion
To our knowledge, this is the first study to compare directly the acute vascular effects of different types of RAS blockade, by using a thorough approach that Figure 2 Box-and-whisker plots of aortic augmentation index (AIx, left plot) and flow-mediated dilation of the brachial artery (FMD, right plot) at baseline and after 2 h, according to treatment. P-values within groups by student's t-test for paired measures. P-values among groups (top of graphs) by one-way ANOVA comparing differences from baseline. ANOVA, analysis of variance.
integrates measures of endothelial function of both conduit and resistance arteries, and central (aortic) haemodynamics. Our data indicate that quinapril and captopril may decrease central BP in an acute setting. Moreover, quinapril also exerts favourable effects on central AIx and conduit artery endothelial function. Notably, these actions of quinapril are independent of accompanying peripheral BP changes; rather, they seem to stem from properties that are inherent to quinapril.
Endothelial function
Quinapril acutely increased the vasodilatory reserve of conduit arteries but not of resistance arteries, whereas captopril and telmisartan lacked any significant effect. The favourable effect of quinapril on FMD is largely attributed to an increase of brachial hyperaemic diameter, given that other parameters that may interfere with FMD, such as resting brachial diameter, reactive hyperaemia, shear stress or the ability of arterial smooth muscle to dilate (expressed by NID), 33, 35 were not affected by any treatment. Quinapril has a higher binding affinity for tissue ACE than captopril 15, 16 and may increase bradykinin and nitric oxide (NO) more potently. 15, 36 NO is the main mediator of FMD 33 and a determinant of arterial elastic properties. 37 Thus, the observed effects of quinapril vs captopril and telmisartan are perhaps due to improved NO bioavailability. The NO pathway contributes more to vasomotion of conduit arteries compared to resistance arteries, 38 so this is perhaps why quinapril had different effects on the brachial artery compared with the forearm vasculature.
Our results are in line with other acute, short-term or chronic studies 16, 27, 39, 40 showing that the vascular effects of high tissue affinity ACEIs are more favourable compared to other types of RAS blockade. We also confirm a previous study showing that acute BP reduction with captopril does not improve FMD. 41 On the other hand, two studies have shown that a single dose of captopril may improve resistance artery vasodilation in hypertensives, but in both studies intrabrachial agonists were used to stimulate the forearm endothelium, 42, 43 so direct comparisons with our study cannot be made.
Central haemodynamics
In our study, quinapril reduced AIx independent of MAP change and also decreased central BPs, but this was not the case for captopril. In general, aortic AIx is determined by heart rate, by the force of cardiac ejection, by the effective length of the arterial system, by the amount of the wave that is reflected back to the aorta (that mainly depends on the tone of the resistance arteries) and finally, by the velocity of the reflected wave (arterial stiffness). 1, 3, 5, 31 As there was no significant difference in P 1 (an expression of cardiac contractility) or heart rate between treatment arms, we conclude that the higher decrement of central SBP with quinapril was predominantly due to lower pressure wave augmentation due to decreased amount and/or delayed timing of pulse-wave reflection.
Consistent with the decreased wave reflection, AIx was significantly lower with quinapril. Although our findings do not substantiate a vasodilatory effect for quinapril, at least in the forearm vessels (resting FBF and FVR, which are measures of the resting tone of small forearm arteries, did not change), we cannot certainly exclude a possible vasodilatory effect on other vascular beds. In substance, this is most probably the case, since DBP and MAP, which correlate with total peripheral resistance, were reduced more with quinapril. This speculative differential effect is in line with evidence showing that oral quinapril inhibits acutely vascular ACE to a greater degree compared with older ACEIs, despite a similar reduction of plasma ACE.
15,16
Although we did not measure pulse-wave velocity in our study, we speculate that quinapril may have favourably affected the timing of wave reflection as well (due to a decrease in arterial stiffness), because (i) quinapril increased both Dt and PP amplification (though nonsignificantly, since our sample size was not powered to detect a significant change of these parameters) and (ii) quinapril improved brachial artery responses (FMD) mediated by NO, which is an important determinant of arterial stiffness. 37 This is in line with evidence showing that quinapril reduces predominantly the stiffness of musculartype arteries, 44 such as the brachial artery and abdominal aorta.
Telmisartan blocks both ACE-and non-ACEproduced angiotensin II 17 , possesses some unique features (such as an ability to activate the peroxisome proliferator-activated receptor-g 28 ), and it has been shown to improve arterial elasticity, central haemodynamics and endothelial function. [45] [46] [47] However, in our acute study, we did not observe any significant effect of telmisartan on arterial function.
Potential clinical implications
Although data with regard to a potential clinical significance of acute improvements of arterial function are lacking, there is some evidence that the acute effects of RAS blockade may be important in some clinical settings, such as acute myocardial infarction, 15, [18] [19] [20] coronary revascularization 19, 21 and during major non-cardiac surgery. 22 Furthermore, some data indicate that high tissue affinity ACEIs may be more beneficial in terms of outcomes in such acute conditions 18 partly because of more favourable effects on factors related to short term prognosis. 21, 23, 24, 48 Our observations provide insights into acute pharmacological actions of different RAS blockers. However, the clinical relevance of the observed differences in acute arterial effects of RAS blockers, if any, is still speculative.
In hypertensive patients, the benefit of antihypertensive treatment is mainly determined by the extent of BP reduction 49 and the long-term effect on cardiovascular structure and function. 8, 9, [11] [12] [13] [14] 39 Recent data support that quinapril and captopril are equally efficient in modifying important surrogate end points with prognostic significance, such as left ventricular mass. 11 On the other hand, some studies have underscored that an improvement of arterial function in hypertensives may benefit prognosis, 5, 7 but there are no trials to directly compare different ACEIs with regard to outcomes. Our findings cannot guide chronic antihypertensive treatment, and they do not suggest, by any means, that quinapril is a better antihypertensive drug. Rather, our observations highlight the need for prospective randomized outcome trials in hypertensive populations to investigate whether these differences in acute arterial effects of RAS blockers are maintained in the long term, and more importantly, whether they translate into differences in clinical outcomes.
Specific comments -limitations
Most patients were using antihypertensive drugs before the study. It is rather unlikely that our main results were influenced by previous treatment, since there were no differences in the frequency of previous drug use across all four subgroups, and furthermore, we evaluated changes of variables from baseline. Our subjects had abstained from their medications for 2 weeks, which is a longer interval than the recommended period of four drug halflives. 33 However, we cannot certainly exclude a possible carry-over effect of previous drug use.
The doses of drugs and the 2-h period were selected based on pharmacokinetics and the timing of maximal BP drop in our pilot study. In other studies that observed acute drug effects on arterial function, these effects occurred almost simultaneously with the BP change. 16, 50 However, because the vascular effects observed in our study were largely BP independent, we cannot preclude possible delayed effects.
Dose may influence the chronic and even the acute vascular effects of some RAS blockers. 8, 50 We used telmisartan 80 mg, since this dose may result in a greater arterial effect compared with lower doses. 50 On the other hand, studies that compared the acute endothelial effects of different ACEIs showed that increasing the dose of the low-tissue affinity ACEI does not modify the effect on arterial function. 25, 26 Furthermore, even a higher dose of captopril (50 mg) does not improve FMD in hypertensive patients. 41 Thus, the doses used in this study seem appropriate to compare the three drugs. However, we cannot certainly rule out further improvements in acute arterial effects with use of significantly higher doses.
In conclusion, our study indicates an acute favourable effect of oral quinapril on peripheral and central arterial function. It suggests that in an acute setting, changes of peripheral BP do not reflect reliably the effect of treatment on vascular performance. Moreover, it seems there are differences between drugs that act on different points of the RAS, and even between drugs of the same class but with different properties regarding their vascular effects. We need further studies to determine whether the observed effects of the different RAS blockers are clinically relevant to chronic treatment of hypertensives or to conditions in which an acute inhibition of the RAS is warranted.
